{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:22:56Z","timestamp":1792606976437,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T00:00:00Z","timestamp":1410825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s40262-014-0182-x","type":"journal-article","created":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T15:42:25Z","timestamp":1420040545000},"page":"81-93","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates"],"prefix":"10.1007","volume":"54","author":[{"given":"Yuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Samineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Mukadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Quan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Girish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Hop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,16]]},"reference":[{"key":"182_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-62703-541-5_1","volume":"1045","author":"I Sasoon","year":"2013","unstructured":"Sasoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol. 2013;1045:1\u201327.","journal-title":"Methods Mol Biol"},{"key":"182_CR2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/antib2010113","volume":"2","author":"PA Trail","year":"2013","unstructured":"Trail PA. Antibody drug conjugates as cancer therapeutics. Antibodies. 2013;2:113\u201329.","journal-title":"Antibodies"},{"key":"182_CR3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4155\/bio.13.38","volume":"5","author":"BA Gorovits","year":"2013","unstructured":"Gorovits BA, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, Siguenza P. Bioanalysis of antibody\u2013drug conjugates: American Association of Pharmaceutical Scientists Antibody\u2013Drug Conjugate Working Group position paper. Bioanalysis. 2013;5:997\u20131006.","journal-title":"Bioanalysis"},{"key":"182_CR4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4155\/bio.12.299","volume":"5","author":"S Kaur","year":"2013","unstructured":"Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguera M. Bioanalytical assay strategies for the development of antibody\u2013drug conjugate biotherapeutics. Bioanalysis. 2013;5:201\u201326.","journal-title":"Bioanalysis"},{"key":"182_CR5","unstructured":"US FDA, Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Application no. 125388 Orig1s000; BLA 125388 and 125399 brentuximab vedotin."},{"key":"182_CR6","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4155\/bio.13.76","volume":"5","author":"D Lu","year":"2013","unstructured":"Lu D, Sahasranaman S, Zhang Y, Girish S. Strategies to address drug interaction potential for antibody\u2013drug conjugates in clinical development. Bioanalysis. 2013;5:1115\u201330.","journal-title":"Bioanalysis"},{"key":"182_CR7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcph.116","volume":"53","author":"TH Han","year":"2013","unstructured":"Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM, O\u2019Connor OA. CYP3A-mediated drug\u2013drug interaction potential and excretion of brentuximab vedotin, an antibody\u2013drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol. 2013;53:866\u201377.","journal-title":"J Clin Pharmacol"},{"key":"182_CR8","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/0006-2952(94)90520-7","volume":"47","author":"JB Houston","year":"1994","unstructured":"Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 1994;47:1469\u201379.","journal-title":"Biochem Pharmacol"},{"key":"182_CR9","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","volume":"27","author":"RS Obach","year":"1999","unstructured":"Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27:1350\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"182_CR10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jps.10005","volume":"91","author":"P Poulin","year":"2002","unstructured":"Poulin P, Theil F-P. Prediction of pharmacokinetics prior to in vivo studies 1. Mechanistic-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129\u201356.","journal-title":"J Pharm Sci"},{"key":"182_CR11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/jps.10539","volume":"93","author":"LM Berezhkovskiy","year":"2004","unstructured":"Berezhkovskiy LM. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci. 2004;93:364\u201374.","journal-title":"J Pharm Sci"},{"key":"182_CR12","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2005;95:1238\u201357.","journal-title":"J Pharm Sci"},{"key":"182_CR13","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1007\/s11095-012-0800-y","volume":"92","author":"K Lin","year":"2012","unstructured":"Lin K, Tibbits J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 2012;92:2354\u201366.","journal-title":"Pharm Res"},{"key":"182_CR14","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/1535-7163.MCT-12-1173","volume":"12","author":"D Li","year":"2013","unstructured":"Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther. 2013;12:1255\u201365.","journal-title":"Mol Cancer Ther"},{"key":"182_CR15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","volume":"39","author":"Y Cao","year":"2012","unstructured":"Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39:711\u201323.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"182_CR16","unstructured":"European Medicines Agency. Assessment report: Adcetris. EMA\/702390\/2012. Procedure number EMEA\/H\/C\/002455. 19 Jul 2012. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002455\/WC500135054.pdf . Accessed 12 Sep 2014."},{"key":"182_CR17","unstructured":"Lu D, Agarwal P, Prabhu S, Nazzal D, Dere R, Saad O, et al. Pharmacokinetics of anti-CD22 and anti-CD79b antibody drug conjugates in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma patients: results from phase 1 dose escalation studies. American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 5\u20139 March 2013; Indianapolis, IN."},{"key":"182_CR18","unstructured":"Oncologic Drugs Advisory Committee. BLA number 125399 (relapsed or refractory systemic anaplastic large cell lymphoma)."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0182-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-014-0182-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0182-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T19:11:07Z","timestamp":1747336267000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-014-0182-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,16]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0182-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,16]]}}}